Carrie Smith Cox
CIK 1110753 · Executive Chair · last filed 2026-05-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MRK price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
2000 GALLOPING HILL ROAD
KENILWORTH, NJ 07033
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SOLV | Director | 16,400 | $86.67 | $1.42M | $0 | 6 | 2026-05-18 |
| TXN | Director | 46,464 | $284.65 | $13.23M | -$17.25M | 42 | 2026-05-14 |
| OGN | Executive Chair | 90,338 | $13.75 | $1.24M | $602.3K | 7 | 2025-11-13 |
| RNAC | Director | 15,629 | $6.42 | $100.3K | $0 | 3 | 2025-01-06 |
| Cartesian Therapeutics, Inc. (SELB) Delisted | Director | 212,881 | $0.88 | $187.6K | $200.5K | 8 | 2023-01-04 |
| CAH | Director | 41,631 | $257.46 | $10.72M | $20.1K | 15 | 2022-11-10 |
| CELGENE CORP /DE/ (CELGZ) Delisted | Director | 0 | — | — | -$2.96M | 16 | 2019-11-22 |
| ECOR | Director | 1,401 | $7.35 | $10.3K | $118.7K | 4 | 2019-06-11 |
| CELGENE CORP /DE/ (CELG) Delisted | Director | 1,130 | — | — | $29.5K | 3 | 2010-06-18 |
| MRK | Executive Vice President | 0 | $149.88 | $0 | -$28.06M | 8 | 2009-11-04 |
Recent Filings · Page 6 of 12
119 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-12-04 | ECOR | Buy (P) | +7,300 | $49.6K | EDGAR |
| 2018-11-13 | CAH | Grant (A) | +3,164 | $0 | EDGAR |
| 2018-11-05 | — | Buy (P) | +3,000 | $50.6K | |
| 2018-10-29 | — | Grant (A) | — | $0 | |
| 2018-08-20 | ECOR | Buy (P) | +3,700 | $50.9K | EDGAR |
| 2018-08-17 | — | Grant (A) | — | $0 | |
| 2018-06-14 | CELGENE CORP /DE/ (CELGZ) Delisted | Mixed | +6,200 | $0 | EDGAR |
| 2018-01-29 | TXN | Grant (A) | +907 | $0 | EDGAR |
| 2017-11-09 | CAH | Grant (A) | +2,623 | $0 | EDGAR |
| 2017-07-31 | TXN | Mixed | — | -$838.3K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.